Molecular Partners Positive Preclinical Data for Next Gen Stem Cell Transplant Leukemia Therapy

 

• Proof-of-concept of Switch-DARPin platform established in vivo, enabling the use of logic-gated and reversible immune activators
• Preclinical safety, efficacy, and pharmacokinetics support MP0621’s potential to selectively kill cKit-positive cells and conditionally block CD47 with limited systemic side effects
• MP0621 presently in IND-enabling studies with Phase 1 in AML anticipated in 2025

https://www.globenewswire.com/news-release/2024/06/14/2898762/0/en/Molecular-Partners-Presents-Positive-Preclinical-Data-for-First-Switch-DARPin-Candidate-MP0621-at-EHA-2024.html